Biosimilar Naming: Distinguishable or Disingenuous?

This is a guest post from Robert Yapundich, MD and Gregory Schimizzi, MD. Dr. Yapundich is a practicing neurologist in Hickory, North Carolina and a member of the Alliance for Patient Access. Dr Schimizzi is a practicing rheumatologist, treasurer of the Coalition of State Rheumatology Organizations and co-convener of the Biologics Prescribers Collaborative. Distinguishable biosimilar naming was the top issue for […]


Drug Patent Expirations for Apr 28, 2016

DrugPatentWatch is your source business intelligence on small-molecule drugs and the 100,000 global patents covering them Click the patents below for more details, or visit DrugPatentWatch.com for more options. ELIDEL (pimecrolimus) Valeant Bermuda Patent number: 6,352,998 Expiration Date: Apr 26, 2016 ZORBTIVE (somatropin recombinant) Emd Serono Patent number: 5,898,030 Expiration Date: Apr 27, 2016 SEROSTIM […]


Drug Patent Expirations for Apr 21, 2016

DrugPatentWatch is your source business intelligence on small-molecule drugs and the 100,000 global patents covering them Click the patents below for more details, or visit DrugPatentWatch.com for more options. LASTACAFT (alcaftadine) Allergan Patent number: 5,468,743 Expiration Date: Apr 20, 2016 DrugPatentWatch provides instant access to actionable insights on pharmaceutical drugs. For more information try a […]


Mainstreaming the Microbiome

This is a guest post from Susan K Finston, President of Finston Consulting. Do you have a response to Susan’s post? Respond in the comments section below. Towards the end of 2015, I wrote about growing recognition of the importance of the microbiome for human health and consequently for commercial biopharmaceutical development here.  Still microbiome research […]


Drug Patent Expirations for Apr 14, 2016

DrugPatentWatch is your source business intelligence on small-molecule drugs and the 100,000 global patents covering them Click the patents below for more details, or visit DrugPatentWatch.com for more options. TOPAMAX (topiramate) Janssen Pharms Patent number: 7,498,311 Expiration Date: Apr 13, 2016 TOPAMAX SPRINKLE (topiramate) Janssen Pharms Patent number: 6,503,884 Expiration Date: Apr 13, 2016 TOPAMAX […]


Drug Patent Expirations for Apr 7, 2016

DrugPatentWatch is your source business intelligence on small-molecule drugs and the 100,000 global patents covering them Click the patents below for more details, or visit DrugPatentWatch.com for more options. ZYRTEC-D 12 HOUR (cetirizine hydrochloride; pseudoephedrine hydrochloride) J And J Consumer Inc Patent number: 6,489,329 Expiration Date: Apr 8, 2016 TYGACIL (tigecycline) Pf Prism Cv Patent […]


Drug Patent Expirations for Mar 31, 2016

DrugPatentWatch is your source business intelligence on small-molecule drugs and the 100,000 global patents covering them Click the patents below for more details, or visit DrugPatentWatch.com for more options. LONSURF (tipiracil hydrochloride; trifluridine) Taiho Oncology Patent number: 5,744,475 Expiration Date: Mar 28, 2016 EMTRIVA (emtricitabine) Gilead Patent number: 5,814,639 Expiration Date: Mar 29, 2016 COMPLERA […]


Drug Patent Expirations for Mar 24, 2016

DrugPatentWatch is your source business intelligence on small-molecule drugs and the 100,000 global patents covering them Click the patents below for more details, or visit DrugPatentWatch.com for more options. INTUNIV (guanfacine hydrochloride) Shire Patent number: 5,854,290 Expiration Date: Mar 21, 2016 PAXIL (paroxetine hydrochloride) Apotex Technologies Patent number: 5,811,436 Expiration Date: Mar 22, 2016 MUSE […]


Which pharmaceutical companies have the most “New Dosage Form” drugs?

New Dosage Forms are one of the categories for which the FDA grants three years of exclusivity for ‘New Clinical Investigations.’ Alternate categories worth of three years of protection include identifying a New Patient Population, New Product, or New Strength. This chart shows the companies which have received the most New Dosage Form exclusivities in […]